Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials
- 10 June 2016
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 78 (1) , 167-171
Abstract
Purpose Tyrosine kinase inhibitor (TKI)-induced thyroid dysfunction has been identified as an important but manageable adverse effect of targeted therapy. Several studies have suggested that patients who develop hypothyroidism respond better to TKIs, but this relationship is not well elucidated. We evaluated the relationship between new-onset hypothyroidism and clinical response in patients with advanced cancers treated with TKIs at our institution. Methods We retrospectively reviewed records for patients from four clinical trials that included at least one TKI therapy between January 2006 and December 2011. Patients with preexisting thyroid disease, including thyroid cancer, hypothyroidism, or hyperthyroidism, were excluded. Analysis of 197 patients was performed. Response was determined using RECIST 1.0. Clinical benefit was described as complete response, partial response, or stable disease greater than 4 months. Multivariable logistic regression analysis was performed to correlate patient characteristics with clinical response. Results The median age for the 197 patients was 58 years (range, 13–85 years), and 56 % were female. Of the 197 patients, 52 (26 %) developed hypothyroidism after therapy. Clinical benefit rates were 50 % in patients with new-onset hypothyroidism versus 34 % in patients without hypothyroidism. In the univariate model, the odds ratio (OR) for new-onset hypothyroidism was 1.9 [95 % confidence interval (CI) (1.0, 3.6) and p = 0.05]. We grouped tumor types into six categories (breast, colorectal carcinoma, melanoma, non-small cell lung cancer, pancreas, and other). When adjusted for tumor type, age (>50 years) and sex, the OR was 2.9 [95 % CI (1.3, 6.5) and p = 0.012] for new-onset hypothyroidism. Conclusion New-onset hypothyroidism was associated with favorable clinical response in patients who received TKI treatment.Keywords
Funding Information
- National Institutes of Health (P30CA016672)
This publication has 22 references indexed in Scilit:
- Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and managementTargeted Oncology, 2011
- Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinibWorld Journal of Urology, 2010
- Hypothyroidism in patients with renal cell carcinomaCancer, 2010
- Efficacy and thyroidal effects of sunitinib in Japanese patients with metastatic renal cell carcinoma: Hypothyroidism and thyroid atrophy as potential biomarkers for sunitinib?Journal of Clinical Oncology, 2009
- Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC)Journal of Clinical Oncology, 2008
- A Novel Tyrosine-Kinase Selective Inhibitor, Sunitinib, Induces Transient Hypothyroidism by Blocking Iodine UptakeThe Journal of Clinical Endocrinology & Metabolism, 2007
- Sunitinib Induces Hypothyroidism in Advanced Cancer Patients and May Inhibit Thyroid Peroxidase ActivityThyroid®, 2007
- Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With SunitinibJNCI: Journal of the National Cancer Institute, 2007
- Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal TumorsAnnals of Internal Medicine, 2006
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000